Inflammation D007249

Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Inflammation

Description

A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.   MeSH

Hierarchy View

Subtype Terms (9)

Acute-Phase Reaction
5 drugs (1 approved, 4 experimental)

Foreign-Body Reaction
1 approved drug

Neurogenic Inflammation
3 drugs (1 approved, 2 experimental)

Neuroinflammatory Diseases
9 drugs (5 approved, 4 experimental)

Seroma
8 drugs (7 approved, 1 experimental)

Serositis
 

Suppuration
 

Systemic Inflammatory Response Syndrome
52 drugs (32 approved, 20 experimental)

Thromboinflammation
 


Phase 4 Indicated Drugs (123)

Other Experimental Indicated Drugs (161)


Organization Involved with Phase 4 Indications (218)

Harbin Medical University

Harvard University

Hayat Pharmaceutical Co. PLC

Helen Keller International

Hospital Clinic of Barcelona

Hospital General Universitario Gregorio Marañon

Hospital Rio Hortega

Hospitalsenhed Midt

Hospital Son Espases

Hospital Son Llatzer

Hospital Universitario Ramon y Cajal

Huazhong University of Science and Technology

Humboldt University

Iladevi Cataract and IOL Research Center

Innovaderm

Innovative Medical Research of South Florida, Inc

Instituto de Medicina Integral Professor Fernando Figueira

Instituto di Biomedicina ed immunologia molecolare

Isfahan University

Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy

Istituto per la Ricerca e l'Innovazione Biomedica

Janssen Pharmaceutica NV

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

Johns Hopkins University

Karolinska Institute

Keryx

Kovach Eye Institute

Kurume University

Laboratoires NEGMA

Laboratorios Poen

Laboratorios Sophia S.A de C.V.

Leiden University

Leo Pharma

LifeBridge Health

Linkoping University

Loyola University

Mahidol University

Maisonneuve-Rosemont Hospital

Mallinckrodt

Mayo Clinic

Medical University of Lodz

Medical University of South Carolina

National Center for Complementary and Integrative Health (NCCIH)

National Cheng Kung University

National Defense Medical College, Japan

National Heart, Lung, and Blood Institute (NHLBI)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Mental Health (NIMH)

National Institutes of Health (NIH)

National Taiwan University

New England Retina Associates

Nizam's Institute of Medical Sciences, Hyderabad, India

Noordwest Ziekenhuisgroep

North Suffolk Mental Health Association

Norwegian University of Science and Technology

Organization Involved with Phase 3 Indications (168)

Organization Involved with Phase 2 Indications (194)

Organization Involved with Other Experimental Indications (182)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.